11 Fastest Growing Penny Stocks to Buy Right Now

Page 8 of 10

3. SCYNEXIS, Inc. (NASDAQ:SCYX)

On February 26, 2026, SCYNEXIS, Inc. (NASDAQ:SCYX) announced that the first participants had been dosed in a Phase 1 single ascending dose and multiple ascending dose trial evaluating the intravenous formulation of its second-generation triterpenoid antifungal therapy, SCY-247. The therapy is being developed as a treatment for invasive candidiasis and as a prophylaxis therapy for invasive fungal disease, with results from the trial expected in 2026.

Earlier, SCYNEXIS, Inc. (NASDAQ:SCYX) said that the U.S. Food and Drug Administration granted Qualified Infectious Disease Product and Fast Track Designations for SCY-247. Further, SCYNEXIS, Inc. (NASDAQ:SCYX) said that it expects to initiate a Phase 1 study of the intravenous formulation and a Phase 2 study of the oral formulation in invasive candidiasis during 2026, and plans to release proof-of-concept data for the oral formulation the same year.

SCYNEXIS, Inc. (NASDAQ:SCYX) said it will also explore potential non-dilutive funding opportunities to support development of the program as antifungal resistance continues to emerge.

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company focused on developing medicines to treat and prevent difficult-to-treat and drug-resistant infections.

Page 8 of 10